---
document_datetime: 2025-11-23 08:10:46
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ivabradine-accord.html
document_name: ivabradine-accord.html
version: success
processing_time: 0.1332945
conversion_datetime: 2025-12-27 16:18:48.120775
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ivabradine Accord

[RSS](/en/individual-human-medicine.xml/65872)

##### Authorised

This medicine is authorised for use in the European Union

ivabradine

Medicine

Human

Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ivabradine Accord](#news-on)
- [More information on Ivabradine Accord](#more-information-on-ivabradine-accord-1125)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Ivabradine Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ivabradine Accord.

For practical information about using Ivabradine Accord, patients should read the package leaflet or contact their doctor or pharmacist.

Expand section

Collapse section

## What is Ivabradine Accord and what is it used for?

Ivabradine Accord is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (heart disease caused by blockage of the blood vessels that supply the heart muscle). The medicine is used in patients with a normal heart rhythm whose heart rate is at least 70 beats per minute. It is used either in patients who cannot take beta?blockers (another type of medicine to treat angina) or in combination with a beta-blocker in patients whose disease is not controlled by beta-blockers alone.

Ivabradine Accord is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) and a normal heart rhythm whose heart rate is at least 75 beats per minute. It is used in combination with standard therapy including beta-blockers, or in patients who cannot be treated with beta-blockers.

Ivabradine Accord contains the active substance ivabradine. It is a 'generic medicine'. This means that Ivabradine Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the European Union (EU) called Procoralan.

## How is Ivabradine Accord used?

Ivabradine Accord is available as tablets (5 and 7.5 mg) and can only be obtained with a prescription. The recommended starting dose is 5 mg twice a day with meals, which the doctor may increase to 7.5 mg twice a day or decrease to 2.5 mg (half a 5-mg tablet) twice a day depending on the patient's heart rate and symptoms. In patients over 75 years old, a lower starting dose of 2.5 mg twice a day can be used. Treatment must be stopped if the heart rate is persistently below 50 beats per minute or if symptoms of bradycardia (slow heart rate) continue. When used for angina, treatment should be stopped if symptoms do not improve after 3 months. Also, the doctor will consider stopping treatment if the medicine has only a limited effect on reducing symptoms or reducing the heart rate.

## How does Ivabradine Accord work?

The symptoms of angina are caused by the heart muscle not receiving enough oxygenated blood. In stable angina, these symptoms occur during physical effort. The active substance in Ivabradine Accord, ivabradine, blocks the 'I f current' in the sinus node, the natural 'pacemaker' that regulates the heart rate. When this current is blocked, the heart rate is lowered, so that the heart has less work to do and needs less oxygenated blood. Ivabradine Accord therefore reduces or prevents the symptoms of angina.

The symptoms of heart failure are caused by the heart not pumping enough blood around the body. By lowering the heart rate, Ivabradine Accord reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.

## How has Ivabradine Accord been studied?

Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Procoralan, and do not need to be repeated for Ivabradine Accord.

As for every medicine, the company provided studies on the quality of Ivabradine Accord. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Ivabradine Accord?

Because Ivabradine Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Ivabradine Accord approved?

The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Ivabradine Accord has been shown to have comparable quality and to be bioequivalent to Procoralan. Therefore, the CHMP's view was that, as for Procoralan, the benefit outweighs the identified risk. The Committee recommended that Ivabradine Accord be approved for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ivabradine Accord?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ivabradine Accord have been included in the summary of product characteristics and the package leaflet.

## Other information about Ivabradine Accord

The European Commission granted a marketing authorisation valid throughout the European Union for Ivabradine Accord on 22 May 2017.

For more information about treatment with Ivabradine Accord, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Ivabradine Accord : EPAR - Summary for the public

Reference Number: EMA/216663/2017

English (EN) (93.98 KB - PDF)

**First published:** 01/06/2017

**Last updated:** 01/06/2017

[View](/en/documents/overview/ivabradine-accord-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-428)

български (BG) (119.9 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/bg/documents/overview/ivabradine-accord-epar-summary-public_bg.pdf)

español (ES) (93.4 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/es/documents/overview/ivabradine-accord-epar-summary-public_es.pdf)

čeština (CS) (118.19 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/cs/documents/overview/ivabradine-accord-epar-summary-public_cs.pdf)

dansk (DA) (92.29 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/da/documents/overview/ivabradine-accord-epar-summary-public_da.pdf)

Deutsch (DE) (94.95 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/de/documents/overview/ivabradine-accord-epar-summary-public_de.pdf)

eesti keel (ET) (92.37 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/et/documents/overview/ivabradine-accord-epar-summary-public_et.pdf)

ελληνικά (EL) (121.92 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/el/documents/overview/ivabradine-accord-epar-summary-public_el.pdf)

français (FR) (94.08 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/fr/documents/overview/ivabradine-accord-epar-summary-public_fr.pdf)

hrvatski (HR) (111.92 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/hr/documents/overview/ivabradine-accord-epar-summary-public_hr.pdf)

italiano (IT) (92.69 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/it/documents/overview/ivabradine-accord-epar-summary-public_it.pdf)

latviešu valoda (LV) (115.31 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/lv/documents/overview/ivabradine-accord-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (116.78 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/lt/documents/overview/ivabradine-accord-epar-summary-public_lt.pdf)

magyar (HU) (113.99 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/hu/documents/overview/ivabradine-accord-epar-summary-public_hu.pdf)

Malti (MT) (261.97 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/mt/documents/overview/ivabradine-accord-epar-summary-public_mt.pdf)

Nederlands (NL) (93 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/nl/documents/overview/ivabradine-accord-epar-summary-public_nl.pdf)

polski (PL) (119.38 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/pl/documents/overview/ivabradine-accord-epar-summary-public_pl.pdf)

português (PT) (93.24 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/pt/documents/overview/ivabradine-accord-epar-summary-public_pt.pdf)

română (RO) (114.51 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/ro/documents/overview/ivabradine-accord-epar-summary-public_ro.pdf)

slovenčina (SK) (118.11 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/sk/documents/overview/ivabradine-accord-epar-summary-public_sk.pdf)

slovenščina (SL) (111.78 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/sl/documents/overview/ivabradine-accord-epar-summary-public_sl.pdf)

Suomi (FI) (92.59 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/fi/documents/overview/ivabradine-accord-epar-summary-public_fi.pdf)

svenska (SV) (99.26 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/sv/documents/overview/ivabradine-accord-epar-summary-public_sv.pdf)

## Product information

Ivabradine Accord : EPAR - Product Information

English (EN) (334.08 KB - PDF)

**First published:** 01/06/2017

**Last updated:** 06/09/2024

[View](/en/documents/product-information/ivabradine-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-873)

български (BG) (551.1 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/bg/documents/product-information/ivabradine-accord-epar-product-information_bg.pdf)

español (ES) (489.27 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/es/documents/product-information/ivabradine-accord-epar-product-information_es.pdf)

čeština (CS) (382 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/cs/documents/product-information/ivabradine-accord-epar-product-information_cs.pdf)

dansk (DA) (406.04 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/da/documents/product-information/ivabradine-accord-epar-product-information_da.pdf)

Deutsch (DE) (317.58 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/de/documents/product-information/ivabradine-accord-epar-product-information_de.pdf)

eesti keel (ET) (393.84 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/et/documents/product-information/ivabradine-accord-epar-product-information_et.pdf)

ελληνικά (EL) (511.4 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/el/documents/product-information/ivabradine-accord-epar-product-information_el.pdf)

français (FR) (421.24 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/fr/documents/product-information/ivabradine-accord-epar-product-information_fr.pdf)

hrvatski (HR) (376.93 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/hr/documents/product-information/ivabradine-accord-epar-product-information_hr.pdf)

íslenska (IS) (398.98 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/is/documents/product-information/ivabradine-accord-epar-product-information_is.pdf)

italiano (IT) (499.42 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/it/documents/product-information/ivabradine-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (422.66 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/lv/documents/product-information/ivabradine-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (446.32 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/lt/documents/product-information/ivabradine-accord-epar-product-information_lt.pdf)

magyar (HU) (419.29 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/hu/documents/product-information/ivabradine-accord-epar-product-information_hu.pdf)

Malti (MT) (465.87 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/mt/documents/product-information/ivabradine-accord-epar-product-information_mt.pdf)

Nederlands (NL) (527.75 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/nl/documents/product-information/ivabradine-accord-epar-product-information_nl.pdf)

norsk (NO) (464.14 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/no/documents/product-information/ivabradine-accord-epar-product-information_no.pdf)

polski (PL) (479.98 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/pl/documents/product-information/ivabradine-accord-epar-product-information_pl.pdf)

português (PT) (472.41 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/pt/documents/product-information/ivabradine-accord-epar-product-information_pt.pdf)

română (RO) (514.52 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/ro/documents/product-information/ivabradine-accord-epar-product-information_ro.pdf)

slovenčina (SK) (467.46 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/sk/documents/product-information/ivabradine-accord-epar-product-information_sk.pdf)

slovenščina (SL) (408.38 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/sl/documents/product-information/ivabradine-accord-epar-product-information_sl.pdf)

Suomi (FI) (623.24 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/fi/documents/product-information/ivabradine-accord-epar-product-information_fi.pdf)

svenska (SV) (488.65 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

06/09/2024

[View](/sv/documents/product-information/ivabradine-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0016/G 31/08/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ivabradine Accord : EPAR - All Authorised presentations

English (EN) (14.78 KB - PDF)

**First published:** 01/06/2017

**Last updated:** 01/06/2017

[View](/en/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-204)

български (BG) (45.27 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/bg/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (25.12 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/es/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (30.91 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/cs/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.92 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/da/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (22.09 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/de/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.54 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/et/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (45.99 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/el/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (25.04 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/fr/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (36.59 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/hr/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (22.83 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/is/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (23.95 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/it/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (45.22 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/lv/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (43.27 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/lt/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (29.99 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/hu/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (38.72 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/mt/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (22.79 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/nl/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (22.79 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/no/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (33.59 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/pl/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (27.58 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/pt/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (38.3 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/ro/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.08 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/sk/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (34.09 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/sl/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.37 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/fi/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.12 KB - PDF)

**First published:**

01/06/2017

**Last updated:**

01/06/2017

[View](/sv/documents/all-authorised-presentations/ivabradine-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ivabradine Accord Active substance ivabradine hydrochloride International non-proprietary name (INN) or common name ivabradine Therapeutic area (MeSH)

- Angina Pectoris
- Heart Failure

Anatomical therapeutic chemical (ATC) code C01EB17

### Pharmacotherapeutic group

Cardiac therapy

### Therapeutic indication

**Symptomatic treatment of chronic stable angina pectoris**

Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ? 70 bpm.

Ivabradine is indicated :

- in adults unable to tolerate or with a contra-indication to the use of beta-blockers

- or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose.

**Treatment of chronic heart failure**

Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ? 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. (see section 5.1)

## Authorisation details

EMA product number EMEA/H/C/004241

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 23/03/2017 Marketing authorisation issued 22/05/2017 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ivabradine Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (167.66 KB - PDF)

**First published:** 08/05/2018

**Last updated:** 06/09/2024

[View](/en/documents/procedural-steps-after/ivabradine-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Ivabradine Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/263015/2017

English (EN) (712.29 KB - PDF)

**First published:** 07/06/2017

**Last updated:** 07/06/2017

[View](/en/documents/assessment-report/ivabradine-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ivabradine Accord

Adopted

Reference Number: EMA/CHMP/146036/2017

English (EN) (84.34 KB - PDF)

**First published:** 24/03/2017

**Last updated:** 24/03/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ivabradine-accord_en.pdf)

#### News on Ivabradine Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-march-2017) 24/03/2017

#### More information on Ivabradine Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-44)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 06/09/2024

## Share this page

[Back to top](#main-content)